Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with
locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a
randomised multicentre, open-label, phase 2 trial. Lancet Oncol
13
(1): 25-32,
doi:S1470-2045(11)70336-9 [pii];10.1016/S1470-2045(11)70336-9 [doi]
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B,
Senn HJ (2013) Personalizing the treatment of women with early breast cancer:
highlights of the St Gallen International Expert Consensus on the Primary Therapy of
Early Breast Cancer 2013. Ann Oncol
24
(9): 2206-2223, doi:mdt303
[pii];10.1093/annonc/mdt303 [doi]
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011)
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the
St. Gallen International Expert Consensus on the Primary Therapy of Early Breast
Cancer 2011. Ann Oncol
22
(8): 1736-1747, doi:mdr304 [pii];10.1093/annonc/mdr304
[doi]
Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I, Jr., Lindquist DL,
Holmes FA, Allison MA, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe
C, Crockett MW, Wang Y, Asmar L, Robert NJ, O'Shaughnessy J (2013) Adjuvant
docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified
early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol
14
(11):
1121-1128,
doi:S1470-2045(13)70384-X
[pii];10.1016/S1470-
2045(13)70384-X [doi]
Kalsi T, Babic-Illman G, Fields P, Hughes S, Maisey N, Ross P, Wang Y, Harari D
(2014) The impact of low-grade toxicity in older people with cancer undergoing
chemotherapy. Br J Cancer
111
(12): 2224-2228, doi:bjc2014496
[pii];10.1038/bjc.2014.496 [doi]
Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Smitt M, Yu R,
Leung AC, Wildiers H (2014) Trastuzumab emtansine versus treatment of physician's
choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a
randomised, open-label, phase 3 trial. Lancet Oncol
15
(7): 689-699, doi:S1470-
2045(14)70178-0 [pii];10.1016/S1470-2045(14)70178-0 [doi]
Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive
heart failure in older women treated with adjuvant anthracycline chemotherapy for
breast cancer. J Clin Oncol
25
(25): 3808-3815, doi:JCO.2006.10.4976
[pii];10.1200/JCO.2006.10.4976 [doi]
Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC,
Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC (2013)
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal
therapy and without chemotherapy in patients with human epidermal growth factor
receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol
31
(14): 1726-
1731, doi:JCO.2012.44.8027 [pii];10.1200/JCO.2012.44.8027 [doi]
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo
HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H,
